Does inflammation shift tryptophan metabolism toward quinolinic acid?

Tryptophan metabolism represents a critical node linking systemic immune activation to neurodegenerative processes, which is highly relevant to age-related inflammatory states.

Inflammatory IDO activation and neurotoxic shifting

• Chronic low-grade inflammation drives the upregulation of indoleamine 2,3-dioxygenase (IDO-1) via intracellular signaling cascades like the JAK-STAT pathway, stimulated by cytokines such as interferon-gamma (IFN-γ), TNF-α, and IL-6.
• This enzymatic activation shunts tryptophan away from serotonin and melatonin synthesis and directs it into the kynurenine pathway, markedly increasing the kynurenine-to-tryptophan ratio.
• Under inflammatory conditions, downstream enzymes like kynurenine 3-monooxygenase (KMO) are upregulated, steering metabolism toward the neurotoxin quinolinic acid.
• Quinolinic acid causes NMDA receptor excitotoxicity and triggers microglial activation, which releases further pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β), establishing a damaging positive feedback loop.

Micronutrient modulation of pathway flux

• Vitamin B6, in its active coenzyme form pyridoxal-5'-phosphate (PLP), is an obligate cofactor for kynureninase (KYNU) and kynurenine aminotransferases (KATs).
• Because KYNU is highly sensitive to PLP depletion compared to KATs, vitamin B6 deficiency selectively suppresses KYNU activity, leading to an accumulation of the pro-oxidant intermediate 3-hydroxykynurenine.
• Niacin-derived NAD and nicotinamide exert direct negative feedback control over hepatic tryptophan 2,3-dioxygenase (TDO2). Adequate niacin levels maintain this inhibition, whereas niacin deficiency relieves it, accelerating overall kynurenine pathway flux.

Bottom line

• Inflammation biases tryptophan metabolism toward neurotoxic quinolinic acid via IDO-1 activation, a pathological shift that is biochemically balanced by vitamin B6 cofactor availability and niacin-dependent feedback regulation of pathway entry.